Bardy Diagnostics (‘BardyDx’), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today that it has raised $35. $5 million in Series B funding, led by River Cities Capital Funds, with the participation of new investors, HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures and Rex Health Ventures. Existing equity investors, SV Health Investors, Health Enterprise Partners and Ascension Ventures have also joined the round. The funds will be used to further accelerate the growth of its innovative P-wave focused cardiac monitoring platform through the expansion of BardyDx’s sales and monitoring services and to support advanced development programs, including enhanced intelligence and visualization technologies.
“In addition to our outstanding existing syndicate of financiers, the size of our new investors underscores the exciting opportunity before us,” said Gust H. Bardy, MD, Founder, Chief Executive Officer of BardyDx “With these funds, we will grow our business by refining and expanding our primary goal of revealing to patients and their physicians the full complexity and significance of their heart rhythm. “That’s right.
BardyDx’s Carnation Ambulatory Monitor (‘CAMTM’) is the industry’s only P-wave centered ambulatory cardiac patch monitor and arrhythmia detection device. The CAM genesis is the result of Dr. Bardy’s frustrations with the fundamental flaws rooted in the development and evolution of cardiac surveillance
“For almost 60 years, standard ECG engineering practices have overprocessed the electrical message of the heart to make it easier for machines to ‘live’ at the expense of losing details in the ECG,” added Dr. Bardy, Bardy “In essence, such legacy engineering does not listen to what the heart is trying to tell us, but rather tells the heart what we are willing to hear. At BardyDx, our pioneering technology focuses on fully unveiling the cardiac rhythm message and thus enables accurate and meaningful patient management based on cardiac truth. “That’s right.
The footprint of BardyDx within the cardiac monitoring industry continues to expand with a growing recognition of innovative P-wave centered technology. The company has recently won the SXSW Impact Pediatric Health Competition, the Children’s National Health System Pediatric Medical Device Innovation Competition, and the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation. “Our capital of the B-Series will continue to fuel the technological innovation that Dr. Bardy has always insisted and for which BardyDx has come to be known,” said Mark Handfelt, Chief Operating Officer of BardyDx.
BardyDx also announced that Rik Vandevenne, Managing Director of River Cities Capital Funds, and Garheng Kong, Managing Director of HealthQuest Capital, will join the Board of Directors of the company.
“You don’t have a chance every day to partner with such a ground-breaking serial entrepreneur and innovator as Dr. Gust Bardy and the BardyDx team,” Vandevenne said. “The company has a clear focus on putting the patient first and has developed a clinically superior ECG platform that revolutionizes heart monitoring. We are excited about the opportunity to help drive further growth for the company while having a positive impact on the lives of thousands of people every week. “That’s right.
About Bardy Diagnosis:
Bardy Diagnosis, Inc. Innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically accurate and patient-friendly cardiac patches and other monitors for the industry. The company’s CAM patch is a non-invasive, P-wave-centric ambulatory cardiac monitor and arrhythmia detection device designed to improve patient compliance for adults and children weighing more than 10 kg (22 lbs) through a lifestyle-enabled design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed in the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary CAM patch technology provides optimal detection and clear recording of the often difficult to detect P-wave, an ECG waveform signal that is essential for accurate arrhythmia diagnosis. Please visit www for more information. Bardydx is Come on,
About the Capital Funds of River Cities:
River Cities is a growth equity firm investing in high-potential health and information technology companies. A consistent, coherent team has enhanced its strategy over six funds with a strong performance River Cities seeks to be a business partner first and a capital provider second, investing significant human capital to leverage its domain expertise and a network of thought leaders over the last 25 years. With $750 million of capital raised and a consistent record of success, River Cities has established itself as the preferred source of growth capital. The firm, headquartered in Cincinnati, OH and Raleigh, NC, is actively seeking new investment for its Fund VI. Please visit www for more information. RCFF Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Bardy%20Diagnostics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
